Holders — by stockHoldings — by fund
Ally Bridge Group (NY) LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001822947
$113.1M
disclosed book value
25
positions
16.6%
largest position share
Positions, as of 2026-06-30
top 25 of 25 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | DFTXDEFINIUM THERAPEUTICS INCCALL | 400,000 | $18.8M | 16.6% |
| 2 | ABVXABIVAX SACALL | 125,000 | $16.7M | 14.7% |
| 3 | NERVMINERVA NEUROSCIENCES INC | 2.2M | $12.1M | 10.7% |
| 4 | PMNPROMIS NEUROSCIENCES INC | 620,319 | $8.2M | 7.2% |
| 5 | TRAXFIRST TRACKS BIOTHERAPEUTICS | 284,287 | $5.7M | 5.1% |
| 6 | AXSMAXSOME THERAPEUTICS INC | 16,493 | $4.0M | 3.6% |
| 7 | ASMBASSEMBLY BIOSCIENCES INC | 140,000 | $3.8M | 3.4% |
| 8 | WHWKWHITEHAWK THERAPEUTICS INC | 817,939 | $3.7M | 3.3% |
| 9 | EWTXEDGEWISE THERAPEUTICS INC | 83,300 | $3.4M | 3% |
| 10 | CLYMCLIMB BIO INC | 249,172 | $3.2M | 2.9% |
| 11 | KURAKURA ONCOLOGY INC | 290,000 | $3.2M | 2.8% |
| 12 | CTMXCYTOMX THERAPEUTICS INC. | 775,000 | $2.9M | 2.6% |
| 13 | AVTXAVALO THERAPEUTICS INC | 150,000 | $2.8M | 2.5% |
| 14 | PALIPALISADE BIO INC | 1.2M | $2.6M | 2.3% |
| 15 | SLDBSOLID BIOSCIENCES INC | 255,959 | $2.6M | 2.3% |
| 16 | ANTXAN2 THERAPEUTICS INC | 526,315 | $2.5M | 2.3% |
| 17 | UROGEN PHARMA LTD | 69,183 | $2.5M | 2.3% |
| 18 | CATXPERSPECTIVE THERAPEUTICS INC | 743,958 | $2.5M | 2.2% |
| 19 | IDYAIDEAYA BIOSCIENCES INC | 67,500 | $2.5M | 2.2% |
| 20 | IVAINVENTIVA SA | 634,800 | $2.4M | 2.1% |
| 21 | ALMSALUMIS INC | 76,459 | $2.2M | 1.9% |
| 22 | OVIDOVID THERAPEUTICS INC | 624,561 | $1.7M | 1.5% |
| 23 | EPRXEUPRAXIA PHARMACEUTICALS INC | 252,175 | $1.7M | 1.5% |
| 24 | IBIOIBIO INC | 390,147 | $682,757 | 0.6% |
| 25 | TRAWTRAWS PHARMA INC | 786,236 | $663,033 | 0.6% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.